Department of Surgery, Section for Hepato-Pancreato-Biliary Surgery, Aarhus University Hospital, Denmark; Department of Clinical Medicine, Aarhus University, Denmark; Department of Surgery, Gødstrup Regional Hospital, Denmark.
Department of Surgery, Section for Hepato-Pancreato-Biliary Surgery, Aarhus University Hospital, Denmark.
Cancer Epidemiol. 2022 Oct;80:102230. doi: 10.1016/j.canep.2022.102230. Epub 2022 Jul 25.
To describe time-trends in incidence, characteristics, treatments, and survival in pancreatic cancer patients in Denmark during 1980-2019.
A nationwide population-based cohort study of all Danish patients diagnosed with exocrine pancreatic cancer during the study period. Data was obtained from individual-level cross linkage between Danish healthcare registries. We present descriptive characteristics and survival estimates, which was obtained using the Kaplan-Meier estimator and Cox proportional hazards regression models.
During the study period, 32,107 patients were diagnosed with pancreatic cancer. In the most recent period, the age-standardized incidence rate was 17.7 per 100,000 person-years. Throughout the study period, between 18.4% and 27.5% of patients had no tumor staging performed, and approximately half of the patient were only offered best supportive care. The proportion of patients treated with surgery doubled during the study period, and the use of adjuvant and neoadjuvant oncological therapy increased substantially. Median survival after surgical resection also increased to 25.8 months in the most recent time period.
Pancreatic cancer incidence is increasing in Denmark, and this increase is projected to continue. The proportion of patients offered curative-intent treatment increased, which translates into an increase in overall survival. All numbers are comparable to best international standards.
描述 1980-2019 年丹麦胰腺癌患者的发病率、特征、治疗方法和生存情况的时间趋势。
一项基于人群的全国性队列研究，纳入了研究期间所有在丹麦被诊断为外分泌胰腺癌的患者。数据来自丹麦医疗保健登记系统的个体层面交叉链接。我们介绍了描述性特征和生存估计，这些估计是使用 Kaplan-Meier 估计器和 Cox 比例风险回归模型获得的。
在研究期间，共有 32107 名患者被诊断为胰腺癌。在最近的时期，年龄标准化发病率为每 100000 人年 17.7 例。在整个研究期间，有 18.4%至 27.5%的患者未进行肿瘤分期，约一半的患者仅接受最佳支持性治疗。手术治疗的患者比例在研究期间翻了一番，辅助和新辅助肿瘤治疗的使用也大幅增加。在最近的时间段，手术后的中位生存时间也增加到 25.8 个月。
在丹麦，胰腺癌的发病率正在增加，预计这种增加将持续下去。接受根治性治疗的患者比例增加，这转化为总体生存率的提高。所有数字都与国际最佳标准相当。
